Identification and characterization of 4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)thiomorpholinecarboxamide (TMI-1), a novel dual tumor necrosis factor-alpha-converting enzyme/matrix metalloprotease inhibitor for the treatment of rheumatoid arthritis.

Identification and characterization of 4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)thiomorpholinecarboxamide (TMI-1), a novel dual tumor necrosis factor-alpha-converting enzyme/matrix metalloprotease inhibitor for the treatment of rheumatoid arthritis.

Tumor necrosis factor (TNF)-alpha is a well validated therapeutic target for the treatment of rheumatoid arthritis. TNF-alpha is initially synthesized as a 26-kDa membrane-bound form (pro-TNF) that is cleaved by a Zn-metalloprotease named TNF-alpha-converting enzyme (TACE) to generate the 17-kDa, so...

Full description

Bibliographic Details
Main Authors: Zhang, Y, Xu, J, Levin, J, Hegen, M, Li, G, Robertshaw, H, Brennan, F, Cummons, T, Clarke, D, Vansell, N, Nickerson-Nutter, C, Barone, D, Mohler, K, Black, R, Skotnicki, J, Gibbons, J, Feldmann, M, Frost, P, Larsen, G, Lin, L
Format: Journal article
Language:English
Published: 2004

Similar Items